Vir Biotechnology, Inc. (VIR)
Every FINRA and SEC series the site collects for Vir Biotechnology, Inc.: short interest with days to cover, daily short sale volume, fails to deliver and Form 4 insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).
19.6M
Short interest
settlement 2026-08-14
13.6
Days to cover
+2.9% vs prior
53.2%
Short share of volume
2026-09-11
1,445
Fails to deliver
settlement 2026-08-11
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-09-11.
Short interest
FINRA, twice a month; the last 12 months shown, all 48 settlements in the JSONAs of 14 August 2026, short interest in VIR is 19,595,909 shares, up 1,142,935 shares over the last month. Over the last 48 readings it ranged from 5,512,667 shares (15 November 2024) to 19,595,909 shares (14 August 2026). The latest reading sits at the top of that range. At the reported average volume of 1.4M shares a day that is 13.6 days to cover, a crowded short.
Embed this chartfree, with the attribution line it carries
<iframe src="https://xoomar.com/embed/stocks/vir" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-08-14 | 19,595,909 | +2.9% | 1,438,318 | 13.62 |
| 2026-07-31 | 19,040,209 | +3.2% | 1,556,119 | 12.24 |
| 2026-07-15 | 18,452,974 | -3.9% | 1,541,749 | 11.97 |
| 2026-06-30 | 19,192,724 | +6.1% | 3,209,850 | 5.98 |
| 2026-06-15 | 18,082,921 | -1.3% | 1,515,506 | 11.93 |
| 2026-05-29 | 18,316,762 | +8.8% | 1,694,464 | 10.81 |
| 2026-05-15 | 16,833,002 | +4.4% | 1,537,245 | 10.95 |
| 2026-04-30 | 16,117,209 | -4.1% | 1,655,187 | 9.74 |
| 2026-04-15 | 16,811,002 | -0.2% | 1,913,227 | 8.79 |
| 2026-03-31 | 16,841,179 | +9.1% | 2,189,726 | 7.69 |
| 2026-03-13 | 15,439,503 | +12.9% | 4,205,902 | 3.67 |
| 2026-02-27 | 13,677,336 | +7.0% | 7,780,284 | 1.76 |
| 2026-02-13 | 12,779,376 | +4.5% | 1,460,546 | 8.75 |
| 2026-01-30 | 12,228,838 | +1.9% | 2,026,916 | 6.03 |
| 2026-01-15 | 11,995,546 | +2.1% | 1,888,247 | 6.35 |
| 2025-12-31 | 11,747,085 | +5.4% | 1,834,443 | 6.40 |
| 2025-12-15 | 11,149,646 | +0.3% | 1,969,263 | 5.66 |
| 2025-11-28 | 11,110,359 | +1.1% | 1,596,727 | 6.96 |
| 2025-11-14 | 10,992,709 | +14.7% | 1,375,156 | 7.99 |
| 2025-10-31 | 9,581,029 | -12.4% | 1,541,962 | 6.21 |
| 2025-10-15 | 10,940,671 | -0.1% | 1,419,550 | 7.71 |
| 2025-09-30 | 10,948,379 | -7.6% | 1,187,216 | 9.22 |
| 2025-09-15 | 11,852,892 | -0.6% | 1,235,525 | 9.59 |
| 2025-08-29 | 11,924,295 | +3.8% | 1,848,201 | 6.45 |
Daily short volume
FINRA Reg SHO, last 60 sessions. JSONAs of 11 September 2026, the short share of VIR volume is 53.2%, down 9.5 points over the last five sessions. Over the last 52 readings it ranged from 21.0% (21 July 2026) to 82.3% (2 September 2026). The latest reading is 8.2 points below the 30-session average of 61.4%, on 881K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-09-11 | 469K | 881K | 53.2% | 401 |
| 2026-09-10 | 477K | 699K | 68.2% | 3,688 |
| 2026-09-09 | 590K | 856K | 69.0% | 4,947 |
| 2026-09-08 | 454K | 592K | 76.7% | 3,387 |
| 2026-09-04 | 266K | 423K | 62.9% | 587 |
| 2026-09-03 | 642K | 1.0M | 62.7% | 100 |
| 2026-09-02 | 1.2M | 1.5M | 82.3% | 343 |
| 2026-09-01 | 821K | 1.1M | 74.7% | 200 |
| 2026-08-31 | 452K | 945K | 47.9% | 0 |
| 2026-08-28 | 436K | 647K | 67.4% | 211 |
| 2026-08-27 | 395K | 655K | 60.3% | 0 |
| 2026-08-26 | 630K | 998K | 63.2% | 3,683 |
| 2026-08-25 | 631K | 1.2M | 51.5% | 0 |
| 2026-08-24 | 289K | 469K | 61.5% | 120 |
| 2026-08-21 | 521K | 757K | 68.8% | 0 |
| 2026-08-20 | 229K | 363K | 63.0% | 52 |
| 2026-08-19 | 333K | 803K | 41.5% | 4,125 |
| 2026-08-18 | 297K | 549K | 54.1% | 2,130 |
| 2026-08-17 | 352K | 556K | 63.4% | 0 |
| 2026-08-14 | 222K | 404K | 54.9% | 0 |
| 2026-08-13 | 295K | 526K | 56.2% | 20 |
| 2026-08-12 | 209K | 298K | 70.1% | 0 |
| 2026-08-11 | 298K | 478K | 62.4% | 4,580 |
| 2026-08-10 | 258K | 467K | 55.4% | 0 |
| 2026-08-07 | 282K | 518K | 54.4% | 1,229 |
| 2026-08-06 | 568K | 885K | 64.2% | 384 |
| 2026-08-05 | 249K | 376K | 66.4% | 100 |
| 2026-08-04 | 279K | 628K | 44.4% | 0 |
| 2026-08-03 | 262K | 401K | 65.4% | 4,033 |
| 2026-07-31 | 222K | 402K | 55.3% | 0 |
Fails to deliver
SEC, by settlement date. JSONAs of 11 August 2026, the fails-to-deliver balance in VIR is 1,445 shares, up 1,262 shares over the last settlement date. Over the last 52 readings it ranged from 1 share (18 June 2026) to 81,409 shares (20 July 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-08-11 | 1,445 | $8.89 | $13K |
| 2026-08-06 | 183 | $9.11 | $2K |
| 2026-08-04 | 12,632 | $8.90 | $112K |
| 2026-07-31 | 22 | $8.90 | $196 |
| 2026-07-30 | 22 | $8.64 | $190 |
| 2026-07-24 | 19,975 | $9.34 | $187K |
| 2026-07-22 | 5,900 | $9.42 | $56K |
| 2026-07-20 | 81,409 | $9.43 | $768K |
| 2026-07-16 | 4 | $9.61 | $38 |
| 2026-07-09 | 114 | $10.43 | $1K |
| 2026-07-07 | 715 | $10.02 | $7K |
| 2026-07-02 | 1,593 | $9.56 | $15K |
| 2026-07-01 | 363 | $10.19 | $4K |
| 2026-06-29 | 23,672 | $10.03 | $237K |
| 2026-06-24 | 3,817 | $10.16 | $39K |
| 2026-06-23 | 55,067 | $9.57 | $527K |
| 2026-06-22 | 57,296 | $9.16 | $525K |
| 2026-06-18 | 1 | $9.30 | $9 |
| 2026-06-15 | 370 | $8.61 | $3K |
| 2026-06-08 | 25,698 | $8.65 | $222K |
| 2026-06-03 | 4,952 | $8.74 | $43K |
| 2026-06-02 | 4,520 | $9.03 | $41K |
| 2026-04-22 | 73 | $10.83 | $791 |
| 2026-04-20 | 1,000 | $10.75 | $11K |
| 2026-04-16 | 632 | $10.46 | $7K |
| 2026-04-09 | 45,958 | $9.52 | $438K |
| 2026-04-07 | 1,000 | $9.06 | $9K |
| 2026-03-31 | 104 | $8.46 | $880 |
| 2026-03-30 | 104 | $8.40 | $874 |
| 2026-03-24 | 8 | $8.84 | $71 |
Insider trades
SEC Form 4, newest first, 50 of 73 shown. JSONNo open-market insider trades were reported for VIR in the last 90 days. The most recent filings are listed below; grants and option exercises carry a weaker signal than voluntary trades. Latest filing: MORE ROBERT J on 2026-08-11.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-08-11 | MORE ROBERT J | n/a | J | 8K | $0.00 | $0 | 41K |
| 2026-06-09 | Coughlin Timothy | n/a | Grant | 8K | $0.00 | $0 | 8K |
| 2026-06-01 | Sabatini Brent | SVP, Chief Accounting Officer | Sell | 379 | $9.45 | $4K | 62K |
| 2026-06-01 | Napolitano Janet | n/a | Sell | 3K | $9.45 | $30K | 21K |
| 2026-05-27 | Sigal Charles Elliott | n/a | Grant | 8K | $0.00 | $0 | 40K |
| 2026-05-27 | Napolitano Janet | n/a | Grant | 8K | $0.00 | $0 | 24K |
| 2026-05-27 | MORE ROBERT J | n/a | Grant | 8K | $0.00 | $0 | 49K |
| 2026-05-27 | Hatfield Jeffrey S. | n/a | Grant | 8K | $0.00 | $0 | 40K |
| 2026-05-27 | Farid Ramy | n/a | Grant | 8K | $0.00 | $0 | 32K |
| 2026-05-27 | BISCHOFBERGER NORBERT W | n/a | Grant | 8K | $0.00 | $0 | 21K |
| 2026-05-01 | SATO VICKI L | n/a | Sell | 22K | $10.05 | $221K | 1.1M |
| 2026-04-29 | De Backer Marianne | President and CEO | J | 234K | $0.00 | $0 | 715K |
| 2026-04-06 | De Backer Marianne | President and CEO | Sell | 73K | $9.16 | $664K | 948K |
| 2026-04-01 | SATO VICKI L | n/a | Sell | 22K | $9.07 | $200K | 1.1M |
| 2026-03-23 | Sabatini Brent | SVP, Chief Accounting Officer | Sell | 8K | $9.12 | $70K | 62K |
| 2026-03-20 | O'Byrne Jason | EVP & Chief Financial Officer | J | 3K | $0.00 | $0 | 160K |
| 2026-03-02 | SATO VICKI L | n/a | Sell | 200 | $9.98 | $2K | 1.1M |
| 2026-03-02 | SATO VICKI L | n/a | Sell | 22K | $9.50 | $207K | 1.1M |
| 2026-02-25 | de Verneuil Vanina | EVP, General Counsel, Corp Sec | Sell | 14K | $9.82 | $135K | 113K |
| 2026-02-25 | Eisner Mark | EVP and Chief Medical Officer | Sell | 2K | $9.82 | $19K | 154K |
| 2026-02-24 | de Verneuil Vanina | EVP, General Counsel, Corp Sec | Sell | 3K | $9.53 | $30K | 127K |
| 2026-02-24 | Sabatini Brent | SVP, Chief Accounting Officer | Sell | 1K | $9.53 | $14K | 70K |
| 2026-02-24 | SATO VICKI L | n/a | Sell | 200 | $10.26 | $2K | 1.1M |
| 2026-02-24 | SATO VICKI L | n/a | Sell | 42K | $9.75 | $411K | 1.1M |
| 2026-02-24 | SATO VICKI L | n/a | Option exercise | 42K | $1.49 | $63K | 1.2M |
| 2026-02-24 | O'Byrne Jason | EVP & Chief Financial Officer | Sell | 2K | $9.53 | $16K | 163K |
| 2026-02-24 | Eisner Mark | EVP and Chief Medical Officer | Sell | 2K | $9.53 | $15K | 156K |
| 2026-02-24 | De Backer Marianne | Chief Executive Officer | Sell | 15K | $9.53 | $141K | 1.0M |
| 2026-02-23 | de Verneuil Vanina | EVP, General Counsel, Corp Sec | Sell | 4K | $7.45 | $33K | 130K |
| 2026-02-23 | Sabatini Brent | SVP, Chief Accounting Officer | Sell | 2K | $7.45 | $14K | 71K |
| 2026-02-23 | O'Byrne Jason | EVP & Chief Financial Officer | Sell | 2K | $7.45 | $16K | 164K |
| 2026-02-23 | Eisner Mark | EVP and Chief Medical Officer | Sell | 2K | $7.45 | $16K | 158K |
| 2026-02-23 | De Backer Marianne | Chief Executive Officer | Sell | 19K | $7.45 | $142K | 1.0M |
| 2026-02-22 | de Verneuil Vanina | EVP, General Counsel, Corp Sec | Grant | 55K | $0.00 | $0 | 134K |
| 2026-02-22 | Sabatini Brent | SVP, Chief Accounting Officer | Grant | 25K | $0.00 | $0 | 73K |
| 2026-02-22 | O'Byrne Jason | EVP & Chief Financial Officer | Grant | 55K | $0.00 | $0 | 166K |
| 2026-02-22 | Eisner Mark | EVP and Chief Medical Officer | Grant | 55K | $0.00 | $0 | 160K |
| 2026-02-22 | De Backer Marianne | Chief Executive Officer | Grant | 285K | $0.00 | $0 | 1.1M |
| 2026-02-13 | Sabatini Brent | SVP, Chief Accounting Officer | Sell | 2K | $7.79 | $12K | 48K |
| 2026-02-02 | SATO VICKI L | n/a | Sell | 22K | $7.71 | $170K | 1.1M |
| 2026-01-02 | SATO VICKI L | n/a | Sell | 22K | $5.93 | $130K | 1.2M |
| 2025-12-01 | SATO VICKI L | n/a | Sell | 22K | $6.00 | $132K | 1.2M |
| 2025-12-01 | SVF Endurance (Cayman) Ltd | n/a | Sell | 192K | $5.98 | $1.1M | 13.7M |
| 2025-11-28 | SVF Endurance (Cayman) Ltd | n/a | Sell | 61K | $6.44 | $396K | 13.9M |
| 2025-11-26 | SVF Endurance (Cayman) Ltd | n/a | Sell | 128K | $6.39 | $818K | 14.0M |
| 2025-11-25 | SVF Endurance (Cayman) Ltd | n/a | Sell | 236K | $6.38 | $1.5M | 14.1M |
| 2025-11-24 | SVF Endurance (Cayman) Ltd | n/a | Sell | 228K | $6.15 | $1.4M | 14.3M |
| 2025-11-17 | O'Byrne Jason | EVP & Chief Financial Officer | Sell | 7K | $5.56 | $38K | 111K |
| 2025-11-05 | de Verneuil Vanina | EVP, General Counsel, Corp Sec | Sell | 2K | $5.16 | $12K | 78K |
| 2025-11-03 | de Verneuil Vanina | EVP and General Counsel | Sell | 1K | $5.86 | $8K | 81K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are the rarer, stronger signal.
Planned sales (Form 144)
Newest first. JSON4 Form 144 notices on file for VIR worth $945K at the prices reported; 4 in the last 90 days worth $945K. Latest: O'Byrne Jason filed on 2026-09-09 to sell 28,333 shares ($315K) from 2026-09-09.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-09 | O'Byrne JasonFormer Officer | 28K | $315K | 0.017% | 2026-09-09 | Fidelity Brokerage Services LLC |
| 2026-08-25 | O'Byrne JasonFormer Officer | 23K | $243K | 0.014% | 2026-08-25 | Fidelity Brokerage Services LLC |
| 2026-08-24 | O'Byrne JasonFormer Officer | 14K | $142K | 0.008% | 2026-08-24 | Fidelity Brokerage Services LLC |
| 2026-08-21 | O'Byrne JasonFormer Officer | 25K | $245K | 0.015% | 2026-08-21 | Fidelity Brokerage Services LLC |
Large holders (13D and 13G)
One row per reporting person, newest filing first. JSON2 holders above 5% have filed on VIR, all on Schedule 13G (passive). The largest reported stake is Vanguard Portfolio Management at 6.8% of the class (11,554,377 shares), filed 2026-07-31 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-07 | 13G | STATE STREET CORPORATIONparent holding company | 10.0M | 5.9% | 2026-06-30 |
| 2026-07-31 | 13G/Ano. 1 | Vanguard Portfolio Managementinvestment adviser | 11.6M | 6.8% | 2026-06-30 |
13F holders
Tracked managers holding VIR at their latest 13F. JSON7 of the 30 tracked managers held VIR at their latest 13F, $100.7M in total at quarter-end prices. Point72 Asset Management is the largest at $57.7M (0.1% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 4 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Point72 Asset Management | 2026-06-30 | 5.7M | $57.7M | 0.06% | +3.7M |
| Two Sigma Investments | 2026-06-30 | 1.1M | $11.3M | 0.01% | -329K |
| Citadel Advisors | 2026-06-30 | 1.0M | $10.6M | 0.00% | -1.2M |
| Renaissance Technologies | 2026-06-30 | 1.0M | $10.4M | 0.01% | +256K |
| AQR Capital Management | 2026-06-30 | 581K | $5.9M | 0.00% | +15K |
| D. E. Shaw & Co. | 2026-06-30 | 416K | $4.2M | 0.00% | -401K |
| Millennium Management | 2026-06-30 | 48K | $489K | 0.00% | -1.3M |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 2026 (quarter ended 2026-06-30) Vir Biotechnology, Inc. reported revenue of $238.9M, up 19582.5% from the same quarter a year earlier, and net income of $80.1M (0.47 diluted EPS). In FY 2025 it generated -$391.8M of operating cash flow.
- Cash
- $278.7M
- Equity
- $982.5M
- Total assets
- $1.21B
- Shares outstanding
- 169,215,958
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $238.9M | $80.1M | 33.5% | 0.47 |
| Q1 2026 | 2026-03-31 | -$29K | -$125.7M | n/a | -0.85 |
| Q4 2025derived | 2025-12-31 | $64.1M | n/a | n/a | n/a |
| Q3 2025 | 2025-09-30 | $240K | -$163.1M | -67975.4% | -1.17 |
| Q2 2025 | 2025-06-30 | $1.2M | -$111.0M | -9139.9% | -0.80 |
| Q1 2025 | 2025-03-31 | $3.0M | -$121.0M | -3989.6% | -0.88 |
| Q4 2024derived | 2024-12-31 | $12.4M | n/a | n/a | n/a |
| Q3 2024 | 2024-09-30 | $2.4M | -$213.7M | -8979.7% | -1.56 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $68.6M | n/a | -$391.8M | $4.8M | n/a | n/a |
| FY 2024 | 2024-12-31 | $74.2M | n/a | -$446.4M | $7.3M | n/a | n/a |
| FY 2023 | 2023-12-31 | $86.2M | n/a | -$778.8M | $21.6M | n/a | n/a |
| FY 2022 | 2022-12-31 | $1.62B | n/a | $1.66B | $68.0M | n/a | n/a |
| FY 2021 | 2021-12-31 | $1.10B | n/a | -$47.6M | $21.8M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are cash paid to repurchase common stock in the year (XBRL PaymentsForRepurchaseOfCommonStock), not authorizations. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-29 from the cover page.
What this page is
Vir Biotechnology, Inc. in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page pulls every series the site collects for one ticker onto one URL, keyed by the SEC's own ticker list, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a summary sentence built from the rows (last value, change, range with dates) and its own JSON and CSV links. Nothing on the page is written by a model; the sentences change only when the data does. A page exists only for companies with data in at least two series, and every section says when its source last updated.
This page follows Vir Biotechnology, Inc. (VIR), SEC CIK 1706431, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.
Source and method
- Short interest
- FINRA consolidated short interestTwice a month, about eight business days after settlement. Latest 2026-08-14.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesEvery trading day, loaded the following morning. Latest 2026-09-11.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataTwice a month, a few weeks after the half month ends. Latest 2026-08-11.JSON and CSV
- Planned sales
- SEC EDGAR Form 144EDGAR read every 30 minutes; a notice is filed on or before the sell order. Latest 2026-09-09.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GEDGAR read every 30 minutes; 13D within five business days of crossing 5%, 13G on the passive schedule. Latest 2026-08-07.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRQuarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC XBRL company factsRefreshed weekly from the SEC's structured data; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Insider trades
- SEC EDGAR Form 4EDGAR read every 30 minutes; filings are due two business days after the trade. Latest 2026-08-11.JSON and CSV
- Company record
- EDGAR filing index for CIK 1706431Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 30 requests a minute without a key, 120 a minute with a key from a free account.
Data checks. Every dataset is checked against its source once a day. This dataset passed the last run, 13 Sep 09:50 UTC.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a crowded short are the combination that has historically preceded squeezes; insider sells next to a crowded short are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as biological products, (no diagnostic substances)
- KYMRKymera Therapeutics, Inc.
- ADPTAdaptive Biotechnologies Corp
- TWSTTwist Bioscience Corp
- HALOHALOZYME THERAPEUTICS, INC.
- KRYSKrystal Biotech, Inc.
- NBIXNEUROCRINE BIOSCIENCES INC
- RVMDRevolution Medicines, Inc.
- AMGNAMGEN INC
- MAZEMaze Therapeutics, Inc.
- GILDGILEAD SCIENCES, INC.
- RXRXRECURSION PHARMACEUTICALS, INC.
- APGEApogee Therapeutics, Inc.
- FENCFENNEC PHARMACEUTICALS INC.
- PCVXVaxcyte, Inc.
- BIIBBIOGEN INC.
- VORVor Biopharma Inc.
- EXELEXELIXIS, INC.
- SRRKScholar Rock Holding Corp
- ADMAADMA BIOLOGICS, INC.
- VCELVericel Corp
- TECHBIO-TECHNE Corp
- ARTVArtiva Biotherapeutics, Inc.
- BCRXBIOCRYST PHARMACEUTICALS INC
- IOVAIOVANCE BIOTHERAPEUTICS, INC.
Datasets
Frequently Asked Questions
How much of VIR is sold short?
What is VIR's daily short volume?
Does VIR have fails to deliver?
Are VIR insiders buying or selling?
Have VIR insiders filed to sell?
Who owns more than 5% of VIR?
What did VIR report last quarter?
Which funds hold VIR?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.